Stock MMQ MIND MEDICINE (MINDMED) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Mind Medicine (MindMed) Inc. Deutsche Boerse AG

Equities

MMQ

CA60255C8850

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 02:00:14 2024-04-18 am EDT 		5-day change 1st Jan Change
8.93 EUR -4.44% Intraday chart for Mind Medicine (MindMed) Inc. -7.93% +176.15%
Apr. 15 Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target MT
Mar. 18 Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital CI

Business Summary

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Number of employees: 57

Managers

Managers TitleAgeSince
Robert Barrow CEO
 Chief Executive Officer - 21-01-13
Schond Greenway DFI
 Director of Finance/CFO 52 22-05-22
Miri Wernli PSD
 President 71 20-02-27
Daniel Karlin CTO
 Chief Tech/Sci/R&D Officer 44 21-01-31
Madeline Feldman ADM
 Chief Administrative Officer - -
Bridget Walton PRN
 Corporate Officer/Principal - 21-12-31
Robert Silva PRN
 Corporate Officer/Principal - 22-04-30
Francois Lilienthal PRN
 Corporate Officer/Principal - 22-04-04
Carrie Liao AUD
 Comptroller/Controller/Auditor 58 21-10-31
Peter Mack PRN
 Corporate Officer/Principal - 21-05-12

Members of the board

Members of the board TitleAgeSince
Andreas Krebs BRD
 Director/Board Member 66 21-09-28
Suzanne Bruhn BRD
 Director/Board Member 60 22-08-10
David Gryska BRD
 Director/Board Member 68 23-06-20
Carol Vallone CHM
 Chairman 67 21-09-28
Roger Crystal BRD
 Director/Board Member 47 22-08-10
Miri Wernli PSD
 President 71 20-02-27
Robert Barrow CEO
 Chief Executive Officer - 21-01-13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 70,267,970 68,571,348 ( 97.59 %) 0 97.59 %

Shareholders

NameEquities%Valuation
Deep Track Capital LP
9.456 %
6,666,667 9.456 % 63 M €
Commodore Capital LP
8.274 %
5,833,333 8.274 % 55 M €
Joe Samberg
1.894 %
1,335,500 1.894 % 13 M €
Ikarian Capital LLC
0.8511 %
600,000 0.8511 % 6 M €
Robert Barrow
0.8230 %
580,202 0.8230 % 5 M €
Vanguard Global Advisers LLC
0.8055 %
567,885 0.8055 % 5 M €
BlackRock Advisors LLC
0.7717 %
544,033 0.7717 % 5 M €
Geode Capital Management LLC
0.5360 %
377,915 0.5360 % 4 M €
Daniel Karlin
0.5084 %
358,452 0.5084 % 3 M €
Susquehanna Securities LLC
0.3263 %
230,051 0.3263 % 2 M €

Company contact information

Mind Medicine (MindMed), Inc.

One World Trade Center Suite 8500

10007, New York

+212-220-6633

http://www.mindmed.co
address Mind Medicine (MindMed) Inc.(MMQ)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.53 USD
Average target price
30.86 USD
Spread / Average Target
+223.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.78% 41.36B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.3B
MODERNA, INC. Stock Moderna, Inc.
+4.01% 39.61B
CELLTRION, INC. Stock Celltrion, Inc.
-15.14% 25.62B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.16% 24.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.08% 18.38B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.67% 11.82B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+24.76% 11.85B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.01% 11.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MNMD Stock
  4. MMQ Stock
  5. Company Mind Medicine (MindMed) Inc.